TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16179039

Group type: EXPERIMENTAL
Intervention: Xenon (Xe, n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Total Intravenous Anaesthesia (TIVA, n = 19)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Xenon (Xe)
Number of subjects: 39

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 39
Study: 11823399

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 32
Study: 10488703

Group type: EXPERIMENTAL
Intervention: Prophylactic banding ligation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study: 9036477

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (administered up to 40 micrograms/kg/min, and atropine when necessary)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 74
Study: 1713985

Group type: EXPERIMENTAL
Intervention: benazepril 10 mg twice daily (b.i.d.) for 2 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 6134884

Group type: EXPERIMENTAL
Intervention: Haemoccult faecal occult blood testing
Number of subjects: 20525

Group type: COMPARATOR
Intervention: Control group (no testing)
Number of subjects: 20525

Group type: EXPERIMENTAL
Intervention: Fibreoptic sigmoidoscopy
Number of subjects: 20525

Group type: EXPERIMENTAL
Intervention: Double-contrast barium enema
Number of subjects: 20525
Study: 30833377

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no epinephrine)
Number of subjects: 0
Study: 29364729

Group type: EXPERIMENTAL
Intervention: Growth emotion mind-sets induction
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Growth emotion mind-sets and failure-is-enhancing beliefs induction
Number of subjects: 630

Group type: COMPARATOR
Intervention: No induction
Number of subjects: 630
Study: 26749431

Group type: EXPERIMENTAL
Intervention: Face-to-face strategy
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Direct mail strategy
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 288
Study: 25567831

Group type: EXPERIMENTAL
Intervention: iPhone application (DizzyFIX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 0
Study: 22627983

Group type: EXPERIMENTAL
Intervention: STeleR intervention (3 home visits, 5 telephone calls, in-home messaging device over 3 months)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: STeleR intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care (routine rehabilitation care as prescribed by physicians)
Number of subjects: 52
Study: 20400183

Group type: EXPERIMENTAL
Intervention: Group 1 (newborns exposed to tactile communication)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group 2 (newborns without communication)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dysphonic Cry
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hyperphonic Cry
Number of subjects: 20
Study: 18827129

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 194
Study: 15886989

Group type: EXPERIMENTAL
Intervention: Cataract surgery in patients with PEX; 171 out of 370 cataract eyes had PEX; 68% had preoperative complications including 89 subluxations, 15 vitreous prolapses, 6 ciliolenticular blocks, and 7 intravitreal dislocations.
Number of subjects: 370

Group type: COMPARATOR
Intervention: Cataract surgery in Omani cataract eyes without PEX; 40 eyes evaluated; endothelial cell count normal compared to age-matched US norm; corneal thickness less than Caucasians but more than Afro-Americans.
Number of subjects: 370
Study: 11913804

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (30 mg kg(‐1) bolus followed by 0.5 g h(‐1) infusion for 20 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (same volume as magnesium)
Number of subjects: 24
Study: 10527970

Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 235

Group type: COMPARATOR
Intervention: Vaginal Hysterectomy
Number of subjects: 235
Study: 7781666

Group type: EXPERIMENTAL
Intervention: Standard activity of 555 MBq 131iodine
Number of subjects: 205

Group type: COMPARATOR
Intervention: Calculated activity to deliver 100 Gy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Radiation dose absorbed by the thyroid
Number of subjects: 205
Study: 2031797

Group type: EXPERIMENTAL
Intervention: iohexol 140 mg I/ml (300 mosm/kg H2O)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml (690 mosm/kg H2O)
Number of subjects: 12

Group type: COMPARATOR
Intervention: diatrizoate 292 mg I/ml (1480 mosm/kg H2O)
Number of subjects: 12
Study: 6628650

Group type: EXPERIMENTAL
Intervention: Spouse‐aided therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 53
Study: 31163544

Group type: EXPERIMENTAL
Intervention: Secretion-free group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Normal bacteria group (oral cavity and skin)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Single non-resistant bacteria group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Fungal group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Compound or multi-drug resistant bacteria group
Number of subjects: 228

Group type: COMPARATOR
Intervention: All groups compared to compound or multi-drug resistant bacteria group
Number of subjects: 228

Group type: COMPARATOR
Intervention: Fungal group compared to non-drug resistant bacteria, normal oral and skin flora, and secretion-free group
Number of subjects: 228

Group type: COMPARATOR
Intervention: Different preoperative secretions classification
Number of subjects: 228
Study: 28633409

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: PD-L1 testing
Number of subjects: 0
Study: 25677311

Group type: EXPERIMENTAL
Intervention: Dedicated bifurcation stent
Number of subjects: 704

Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 704
Study: 24497205

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23020650

Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg once-daily
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 19664404

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 10917

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10917
Study: 17504339

Group type: EXPERIMENTAL
Intervention: PPH with additional surgical intervention
Number of subjects: 310

Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy
Number of subjects: 310
Study: 16941069

Group type: EXPERIMENTAL
Intervention: Valsalvometer (forced expiration through a flow restriction device)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Valsalva manoeuvre (following standardised verbal instruction)
Number of subjects: 100
Study: 14971530

Group type: EXPERIMENTAL
Intervention: Pre-operative vaginal douching with 1 per cent povidone-iodine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no vaginal douching)
Number of subjects: 300
Study: 11005562

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy with 60 MBq 99mTc‐nanocolloid (1.6 mCi)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 200
Study: 9097895

Group type: EXPERIMENTAL
Intervention: Testosterone (50, 100, and 200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8474402

Group type: EXPERIMENTAL
Intervention: 9 g fish oil (3.15 g n-3 fatty acids per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 9 g olive oil
Number of subjects: 0
Study: 3546166

Group type: EXPERIMENTAL
Intervention: Curcumin (diferuloyl methane)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30993341

Group type: EXPERIMENTAL
Intervention: Organic trace minerals (OTM) supplementation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Inorganic trace minerals (ITM) supplementation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Progeny of OTM-fed breeders
Number of subjects: 128

Group type: COMPARATOR
Intervention: Progeny of ITM-fed breeders
Number of subjects: 128
Study: 28698009

Group type: EXPERIMENTAL
Intervention: epacadostat 600mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: tamoxifen 20mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: epacadostat
Number of subjects: 42

Group type: COMPARATOR
Intervention: tamoxifen
Number of subjects: 42
Study: 25726399

Group type: EXPERIMENTAL
Intervention: Aluminum oxide discs (n = 10)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Multilaminated carbide burs (n = 10)
Number of subjects: 10
Study: 23140805

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual Psychotherapy (IP)
Number of subjects: 0
Study: 21954640

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 19269938

Group type: EXPERIMENTAL
Intervention: Standardized protocol training for palpatory assessment of the frontomalar suture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 36
Study: 16633141

Group type: EXPERIMENTAL
Intervention: Itraconazole pretreatment (200 mg/d for 10 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Itraconazole pretreatment with CYP2D6*10/*10 genotype
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CYP2D6*10 genotype with itraconazole pretreatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10 genotype with itraconazole pretreatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 19
Study: 14983418

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Abstracts from 1998 and 1999
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Abstracts from 1987
Number of subjects: 63
Study: 11514765

Group type: EXPERIMENTAL
Intervention: Gamma nail intramedullary fixation device
Number of subjects: 400

Group type: COMPARATOR
Intervention: Richard's sliding hip screw and plate
Number of subjects: 400
Study: 9667721

Group type: EXPERIMENTAL
Intervention: Elective proximal gastric vagotomy (PGV)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Medical treatment with H2-receptor antagonists
Number of subjects: 3

Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 3
Study: 7851061

Group type: EXPERIMENTAL
Intervention: 10 kg weight in one hand
Number of subjects: 12

Group type: COMPARATOR
Intervention: no weight
Number of subjects: 12
Study: 2901569

Group type: EXPERIMENTAL
Intervention: Electrical nerve stimulation (ENS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo-ENS
Number of subjects: 24
Study: 29231499

Group type: EXPERIMENTAL
Intervention: Combination group (acupuncture plus ginger moxibustion at Heding EX-LE 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture group (simple acupuncture at Heding EX-LE 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ginger moxibustion group (simple ginger moxibustion at Heding EX-LE 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ginger moxibustion group
Number of subjects: 90
Study: 25488262

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (108 cfu) with 400 UI of vitamin D3
Number of subjects: 105

Group type: COMPARATOR
Intervention: 400 UI of vitamin D3
Number of subjects: 105
Study: 23123925

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (BUD/FM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide (BUD)
Number of subjects: 0
Study: 20738748

Group type: EXPERIMENTAL
Intervention: 0.25% Lawsone Methyl Ether (LME)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.025% Lawsone Methyl Ether (LME)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lawsone Methyl Ether (LME)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.12% Chlorhexidine (CHX)
Number of subjects: 54
Study: 19103435

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16826106

Group type: EXPERIMENTAL
Intervention: Periapatite-coated Duracon implants
Number of subjects: 26

Group type: COMPARATOR
Intervention: Uncoated Duracon implants
Number of subjects: 26
Study: 15247013

Group type: EXPERIMENTAL
Intervention: Vitamin E, 300 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multivitamin, two tablets t.i.d.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immun‐Age 6 g/day nocte
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (10 dyspeptic patients)
Number of subjects: 60
Study: 11207103

Group type: EXPERIMENTAL
Intervention: Waterbirth pool
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Augmentation of labour
Number of subjects: 220

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 220
Study: 9091151

Group type: EXPERIMENTAL
Intervention: Zinc oxide impregnated bandage
Number of subjects: 113

Group type: COMPARATOR
Intervention: Zinc oxide impregnated stockingette
Number of subjects: 113

Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 113
Study: 8452189

Group type: EXPERIMENTAL
Intervention: Single-dose fleroxacin (400 mg)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: 7-day fleroxacin (200 mg once a day)
Number of subjects: 961

Group type: COMPARATOR
Intervention: 7-day ciprofloxacin (250 mg twice a day)
Number of subjects: 961
Study: 3779034

Group type: EXPERIMENTAL
Intervention: Nifurzide (600 mg single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifuroxazide (600 mg single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14C-nifurzide (10 mg kg-1 in rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14C-nifuroxazide (10 mg kg-1 in rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14C-nifuroxazide (in rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14C-nifurzide (in rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14C-nifurzide and 14C-nifuroxazide (in rats)
Number of subjects: 0
Study: 31740197

Group type: EXPERIMENTAL
Intervention: EPA (1 g per day for 6 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DPA (1 g per day for 6 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DHA (1 g per day for 6 days)
Number of subjects: 12
Study: 27635620

Group type: EXPERIMENTAL
Intervention: Preradiation chemotherapy with cisplatin, etoposide, cyclophosphamide, and vincristine followed by craniospinal radiation (CSI)
Number of subjects: 11
Study: 26463725

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABLA-12 with 50 mg of fructooligosaccharide)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (rice maltodextrin)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 225
Study: 25695111

Group type: EXPERIMENTAL
Intervention: Stage N3 (% TST)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Stage N1 (% TST)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Higher sleep efficiency
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Longer TST
Number of subjects: 118
Study: 23918376

Group type: EXPERIMENTAL
Intervention: Meditation training (5 hours total over 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation training control
Number of subjects: 0
Study: 20634131

Group type: EXPERIMENTAL
Intervention: TENS at 5 Hz
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TENS at 25 Hz
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TENS at 50 Hz
Number of subjects: 9
Study: 18333763

Group type: EXPERIMENTAL
Intervention: Manual breast pump
Number of subjects: 280

Group type: COMPARATOR
Intervention: Electric breast pump
Number of subjects: 280
Study: 16830932

Group type: EXPERIMENTAL
Intervention: ECG-derived method for estimating respiratory frequency
Number of subjects: 34
Study: 14667998

Group type: EXPERIMENTAL
Intervention: 1 mg onapristone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 10 mg onapristone
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2 mg of oestradiol
Number of subjects: 17
Study: 10923059

Group type: EXPERIMENTAL
Intervention: Critical tests administered at the beginning and end of the session
Number of subjects: 351

Group type: COMPARATOR
Intervention: Critical tests administered only once, at the end of the session
Number of subjects: 351
Study: 9678101

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) for 36 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no OCs)
Number of subjects: 17
Study: 8099592

Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3558328

Group type: EXPERIMENTAL
Intervention: lorazepam 1 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: alprazolam 0.5 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: lorazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: alprazolam
Number of subjects: 30
Study: 31567609

Group type: EXPERIMENTAL
Intervention: 1,500-nm nonablative fractional laser (NAFL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10,600-nm ablative fractional laser (AFL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both NAFL and AFL
Number of subjects: 100
Study: 30542407

Group type: EXPERIMENTAL
Intervention: tiotropium bromide combined with budesonide/formoterol
Number of subjects: 180

Group type: COMPARATOR
Intervention: budesonide/formoterol (control group)
Number of subjects: 180
Study: 25711125

Group type: EXPERIMENTAL
Intervention: Parental presence at clinical bedside rounds (PPCBR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-parental presence at clinical bedside rounds (non-PPCBR)
Number of subjects: 72
Study: 23833867

Group type: EXPERIMENTAL
Intervention: High-reward group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-reward group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compensation shock condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-compensation shock condition
Number of subjects: 0
Study: 20598123

Group type: EXPERIMENTAL
Intervention: Supervised implementation of the oral health care guideline and daily oral health care protocol
Number of subjects: 720

Group type: COMPARATOR
Intervention: Non-supervised implementation of the oral health care guideline
Number of subjects: 720
Study: 18249330

Group type: COMPARATOR
Intervention: Hepcon heparin management system (HMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified ACT-based heparinization
Number of subjects: 0
Study: 17236474

Group type: EXPERIMENTAL
Intervention: Assistive technology supplement to the School Function Assessment
Number of subjects: 28

Group type: COMPARATOR
Intervention: School Function Assessment
Number of subjects: 28
Study: 14604321

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine plus 1 microg/mL fentanyl
Number of subjects: 210
Study: 15244185

Group type: EXPERIMENTAL
Intervention: 350 mg/m2 irinotecan every three weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 mg/m2 irinotecan once a week for four weeks followed by a two-week drug-free interval
Number of subjects: 0
Study: 11220295

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 1.0 mg b.i.d.
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2.0 mg b.i.d.
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 7551204

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 28
Study: 1722564

Group type: EXPERIMENTAL
Intervention: ABVP/LOPP (doxorubicin, bleomycin, vinblastine, prednisone alternating with lomustine, vincristine, procarbazine, prednisone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: COPP-Bleo (cyclophosphamide, vincristine, procarbazine, prednisone, low dose of bleomycin)
Number of subjects: 80
Study: 7051404

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 350

Group type: COMPARATOR
Intervention: Non-pulsatile perfusion
Number of subjects: 350
Study: 2861523

Group type: EXPERIMENTAL
Intervention: J5 antibody recipients
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control (plasma from donors before immunisation)
Number of subjects: 262
Study: 30953222

Group type: EXPERIMENTAL
Intervention: LMA-Protector
Number of subjects: 100

Group type: COMPARATOR
Intervention: LMA-Supreme
Number of subjects: 100
Study: 30515431

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1 and then 5 mg/kg once daily for 4 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxicillin (25 mg/kg/d twice‐daily for 5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (240 mg once daily for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28606591

Group type: EXPERIMENTAL
Intervention: rVSV∆G-ZEBOV-GP vaccine at 2×10^7 PFU dose
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: rVSV∆G-ZEBOV-GP vaccine
Number of subjects: 513
Study: 26253622

Group type: EXPERIMENTAL
Intervention: 20mg vortioxetine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40mg vortioxetine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20mg paroxetine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23018908

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (100/25 μg)
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg)
Number of subjects: 16000

Group type: EXPERIMENTAL
Intervention: Vilanterol (25 μg)
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 16000